Table 4.
Published reproductive and oncologic outcomes after FST of adenosarcoma.
| Study, Year [Ref] |
Design | FST Patients (n) |
Age (Median, Range) |
Parity | Surgery | Adjuvant Treatment | Follow Up (Median, Range) |
Recurrence, n (%) | Death, n (%) | Total Pregnancies (n) | ART (n) |
Details |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zizolfi, 2021 [36] | Case report | 1 | 23 | NU | HR | MA 160 mg/day | 60 | 0 | 0 | 1 | 0 | Full-term VB |
| Yuan, 2019 [16] | Retrospective | 9 (cervical: 5; uterine body: 4 |
25 (19–34) | NA | HR: 9 | CT: 3 MA/MPA: 3 No: 3 |
19 (15–62) | 1 (11.1) | 0 | 1 | 0 | Full-term VB |
| Goh, 2018 [37] | Case report | 1 | 21 | NU | Polipectomy | - | 139 | 1 (100) | 0 | 1 | - | Full-term VB |
| Togami, 2018 [17] | Retrospective | 1 (cervical) |
17 | NU | Conization | - | 62 | 0 | 0 | 0 | - | - |
| Lee, 2017 [18] | Retrospective | 7 | 27 (21–40) | NU: 7 | HR: 5; cervical excision: 1; dilatation and curettage: 1 | MPA: 1; CT (IFO + DDP): 1 No: 5 |
NA | 2 (28.6) | 0 | 1 | 0 | Full-term VB |
ART: assisted reproductive technology; CT: chemotherapy; DDP: cisplatin; FST: fertility-sparing treatment; HR: hysteroscopic resection; IFO: ifosfamide; MA: megestrol acetate; MPA: medroxyprogesterone acetate; n: number; NU: nulliparous; VB: vaginal birth.